Author Question: A male patient is being treated for infertility. The nurse evaluates that treatment has met the goal ... (Read 22 times)

tiffannnnyyyyyy · **on:** Jul 23, 2018

A male patient is being treated for infertility. The nurse evaluates that treatment has met the goal of endocrine pharmacotherapy if which finding is assessed?

1. Patient reports reduced difficulty in achieving and maintaining an erection.
2. Patient's sperm count is 22 million/mL.
3. Patient's ejaculate volume is 2 mL.
4. Patient reports pleasure with intercourse.

Question 2

What type of drugsareonabotulinu mtoxin A (Botox) and rimabotulinumtoxin B (Myobloc)?

1. Peripherally acting antispasmodic
2. Indirect-acting antispasmodic
3. Centrally acting antispasmodic
4. Direct-acting antispasmodic

tranoy · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

2
Rationale 1: The patient's ability to sustain an erection is not a criterion for success of endocrine pharmacotherapy for infertility.
Rationale 2: The goal of endocrine pharmacotherapy is to increase sperm production. A sperm count of 22 million/mL is normal.
Rationale 3: The amount of ejaculate volume is not a criterion for success of endocrine pharmacology for infertility.
Rationale 4: Patient's pleasure with intercourse is not a criterion for success of endocrine pharmacology for infertility.

Global Rationale: The goal of endocrine pharmacotherapy is to increase sperm production. A sperm count of 22 million/mL is normal. The patient's ability to sustain an erection, the amount of ejaculate, and patient's pleasure with intercourse are not criteria for success of endocrine pharmacotherapy for infertility.

Answer to Question 2

4

Rationale 1: Onabotulinumtoxin A (Botox) and rimabotulinumtoxin B (Myobloc) are direct-acting antispasmodics.
Rationale 2: Onabotulinumtoxin A (Botox) and rimabotulinumtoxin B (Myobloc) are direct-acting antispasmodics.
Rationale 3: Onabotulinumtoxin A (Botox) and rimabotulinumtoxin B (Myobloc) are direct-acting antispasmodics.
Rationale 4: Onabotulinumtoxin A (Botox) and rimabotulinumtoxin B (Myobloc) are direct-acting antispasmodics.

Global Rationale: Onabotulinumtoxin A (Botox) and rimabotulinumtoxin B (Myobloc)are direct-acting antispasmodics. They are not peripherally acting antispasmodics, indirect-acting antispasmodics, or centrally acting antispasmodics.